Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 1999 June;43(2) > The Quarterly Journal of Nuclear Medicine 1999 June;43(2):119-24

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  RADIOPHARMACOLOGYFREEfree


The Quarterly Journal of Nuclear Medicine 1999 June;43(2):119-24

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Polypeptides from phage display. A superior source of in vivo imaging agents

Ladner R. C.

From the Dyax Corp., Therapeutic and Diagnostic Division Cambridge, Massachusetts, USA


FULL TEXT  


To ­decide wheth­er expe­ri­ence teach­es ­that ­small pro­teins and con­strained pep­tides hav­ing ­high affin­ity for molec­u­lar tar­gets can be engi­neered to ­have suit­able phar­ma­cok­i­net­ics for imag­ing. Phage dis­play, a molec­u­lar diver­sity tech­nol­o­gy, ­allows selec­tion of poly­pep­tides hav­ing ­high affin­ity and spec­i­fic­ity for ­almost any tar­get. These poly­pep­tides can be mod­i­fied in ­ways ­that ­improve phar­ma­cok­i­net­ics ­with accept­able ­impact on bind­ing. Often, rel­a­tive­ly few chang­es con­fers phar­ma­cok­i­net­ics suit­able for imag­ing on poly­pep­tides select­ed for affin­ity and spec­i­fic­ity to a tar­get and for stabil­ity. It is like­ly ­that few var­i­ants of ­phage-select­ed pro­teins and con­strained pep­tides ­will ­need to be test­ed to ­obtain a use­ful imag­ing ­agent.

top of page

Publication History

Cite this article as

Corresponding author e-mail